To the best of our knowledge, this study is the first to explore various pathogenic mutations presented in patients on the HER2 interaction domains, aiming to elucidate their impact on interaction dynamics and, consequently, dictating the therapeutic response to the personalized medicines in BC cells. This evidence concerns the gene ERBB2 and breast cancer.